Company intelligence / Profile preview

Point6 Bio

Not specified, Not specified, Israelpoint6.bio ↗

Ownership: Private
Development stage: Other

Overview

Point6 Bio has developed a proprietary multi‑omics platform that integrates biological expertise and machine learning to identify nuanced molecular processes. Their lead solution aims to provide a non-invasive, biomarker-based diagnostic for Autism Spectrum Disorder. The company builds on years of neuroscientific research but has not yet reported clinical trial results or commercialized products.

Therapeutic areas: Psychiatry
Modalities: Biomarker-based diagnosticsmulti-omics analysis (including proteomics and gut microbiome)
Industry: Molecular Diagnostics

Partnerships

VLX Ventures (incubator/investor partnership)

Beyond the preview

Go deeper on Point6 Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Point6 Bio.

Explore the full profile